Skip to content
Sign in
Business opportunities for Wink Biotherapeutics

Compatibility /100

45/100

Medium potential

Why talk

  1. Both are based in United States: shared local customers, investors and ecosystem.
  2. Wink Biotherapeutics likely needs funding for the next round — ZymoChem (United States, Series A, $25M raised) can offer investor introductions (inferred from public profile).
  3. ZymoChem has raised about $25M — investor introductions are realistic.

Score anatomy

Each segment is what one dimension adds, out of 100.

Needs ↔ offers12.5Market bridge15.7Customer potential0.0Sector synergy7.5Stage complementarity9.0

Dimension by dimension

Needs ↔ offers

12.5 / 25 pts

ZymoChem can help Wink Biotherapeutics.

  • Wink Biotherapeutics likely needs funding for the next round — ZymoChem (United States, Series A, $25M raised) can offer investor introductions (inferred from public profile).

Market bridge

15.7 / 45 pts

Distant markets.

  • Both are based in United States: shared local customers, investors and ecosystem.

Customer potential

0.0 / 10 pts

Neither side has a product on the market yet.

No supporting signal in the records.

Sector synergy

7.5 / 10 pts

Same sector: peers.

  • Same sector (Biotech & life sciences): peer learning on regulation, pricing and investors; Wink Biotherapeutics works on RNA aptamers – type 1 diabetes and solid tumors, ZymoChem on Synthetic biology – bio-based materials.

Stage complementarity

9.0 / 10 pts

Strong mentoring / investor-intro potential.

  • ZymoChem has raised about $25M — investor introductions are realistic.
  • ZymoChem (Series A) is well ahead of Wink Biotherapeutics (Pre-seed): mentoring and investor intros.

How the score works

Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “Market entry”: Needs ↔ offers 25, Market bridge 45, Customer potential 10, Sector synergy 10, Stage complementarity 10. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.

Potential blends compatibility (65%) with the mean global score of both startups (35%): 46/100 — high from 50, medium from 36.